Novo Nordisk open to M&A to strengthen weight-loss drug pipeline, CEO says

Novo Nordisk is open to pursuing M&A opportunities to strengthen its weight-loss drug pipeline, according to the CEO. Simultaneously, Viking Therapeutics experienced a significant 27% surge in its stock price following the release of new weight loss drug data. Both companies are actively operating within the competitive weight-loss medication market, with Novo Nordisk focusing on strategic acquisitions and Viking Therapeutics benefiting from positive clinical results that have driven substantial investor interest and market growth.